stoxline Quote Chart Rank Option Currency Glossary
  
Liminal BioSciences Inc. (LMNL)
8.5  0.01 (0.12%)    09-25 15:59
Open: 8.48
High: 8.5
Volume: 5,055
  
Pre. Close: 8.49
Low: 8.48
Market Cap: 28(M)
Technical analysis
2023-10-20 4:24:52 PM
Short term     
Mid term     
Targets 6-month :  9.92 1-year :  11.59
Resists First :  8.5 Second :  9.92
Pivot price 8.45
Supports First :  8.41 Second :  8.36
MAs MA(5) :  8.48 MA(20) :  8.44
MA(100) :  7.59 MA(250) :  5.95
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  96.6 D(3) :  88.8
RSI RSI(14): 76.4
52-week High :  8.5 Low :  3.09
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LMNL ] has closed below upper band by 13.8%. Bollinger Bands are 84.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.5 - 8.55 8.55 - 8.58
Low: 8.4 - 8.44 8.44 - 8.48
Close: 8.43 - 8.5 8.5 - 8.56
Company Description

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Headline News

Tue, 26 Sep 2023
Liminal Biosciences Announces Completion of the Plan of Arrangement With Structured Alpha LP - BioSpace

Wed, 12 Jul 2023
LMNL Skyrockets on Acquisition by Structured Alpha - TipRanks.com - TipRanks

Wed, 12 Jul 2023
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management - MarketWatch

Wed, 05 Apr 2023
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today? - InvestorPlace

Thu, 26 Jan 2023
Liminal BioSciences Announces Reverse Stock Split - Canada NewsWire

Thu, 21 Jul 2022
Liminal BioSciences Announces Discontinuation of Fezagepras Development - Canada NewsWire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 1.26e+006 (%)
Held by Institutions 61.2 (%)
Shares Short 1 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.147e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 267.4 %
Operating Margin -6 %
Return on Assets (ttm) 502.6 %
Return on Equity (ttm) -39 %
Qtrly Rev. Growth 492000 %
Gross Profit (p.s.) -0.98
Sales Per Share -4.84
EBITDA (p.s.) -507839
Qtrly Earnings Growth -6.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -36 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -1.76
Price to Cash Flow 37.72
Stock Dividends
Dividend 0
Forward Dividend 675
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android